Real World Evidence (RWE) 101
An Introduction to Real World Evidence Concepts, Insights, and Practical Application
Real World Evidence (RWE) 101 – SOPs and Regional Regulations
RWE 101 - SOPs and Regional Regulations In the realm of quality assurance (QA), it's vital that standard operating procedures (SOPs) are crafted in a way that accurately and [...]
Real World Evidence (RWE) 101 – Standard Operating Procedures
RWE 101 - Standard Operating Procedures Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance [...]
Real World Evidence (RWE) 101 – Publications
RWE 101 - Publications The term RWE stands for Real-World Evidence, which is evidence derived from real-world data (RWD). RWD are data relating to patient health status and/or the [...]
Real World Evidence (RWE) 101 – Archiving Specifics
RWE 101 - Archiving Specifics Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory [...]
Real World Evidence (RWE) 101 – Archiving Generics
RWE 101 - Archiving Generics In the context of health research, both observational studies and clinical trials are crucial for understanding disease processes, patient outcomes, and the safety and [...]
Real World Evidence (RWE) 101 – Study Close-out
RWE 101 - Study Close-Out Closing out an observational study involves several key steps to ensure that all study activities are concluded properly, and data integrity is maintained. Here [...]
RWE 101 Topics
- 4 Potential Uses for Improving Drug Development [Link] [LinkedIn]
- Purpose of Real World Evidence [Link] [LinkedIn]
- The Role of RWE in the Context of Digital Health [Link] [LinkedIn]
- What is the Connection between Real World Data (RWD) and Real World Evidence (RWE)? [Link] [LinkedIn]
- How Robust is RWE? [Link] [LinkedIn]
- Is Real World Evidence a Replacement for Clinical Trials? [Link] [LinkedIn]
- The Evolution of Real World Evidence Regulations [Link] [LinkedIn]
- Do I Need IRB Approval for My Observational Study? [Link] [LinkedIn]
- What is the Difference Between an IRB and a REC? [Link] [LinkedIn]
- Why is there so much excitement about the use of AI in the context of real world evidence? [Link] [LinkedIn]
- Secondary Use of Existing Data [Link] [LinkedIn]
- Primary Data versus Secondary Data [Link] [LinkedIn]
- Data Tokenization [Link] [LinkedIn]
- De-Identification versus Pseudo-Anonymisation [Link] [LinkedIn]
- The Impact of GDPR on RWE Research [Link] [LinkedIn]
- Ethical Foundation of RWE Research [Link] [LinkedIn]
- The Declaration of Helsinki [Link] [LinkedIn]
- Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence [Link] [LinkedIn]
- Is ICH GCP Applicable to Non-Interventional Studies? [Link] [LinkedIn]
- EMA Good Pharmacovigilance Practices (GVPs) [Link] [LinkedIn]
- ISPE GPP [Link] [LinkedIn]
- The Patient Voice [Link] [LinkedIn]
- Diversity [Link] [LinkedIn]
- Pregnancy Registries [Link] [LinkedIn]
- Registry vs Registry-Based Study [Link] [LinkedIn]
- DARWIN-EU [Link] [LinkedIn]
- The Impact of the EMAs Data Quality Framework on RWE [Link] [LinkedIn]
- The European Health Data Space (EHDS) [Link] [LinkedIn]
- Federated Clinical Data [Link] [LinkedIn]
- EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research? [Link] [LinkedIn]
- Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’? [Link] [LinkedIn]
- Acknowledgement of the Limitations of Clinical Trials and RWE Studies [Link] [LinkedIn]
- Challenges Pharma Companies Face when Using RWE to Support Marketing Authorisations [Link] [LinkedIn]
- Challenges in RWE Generation (Regulatory Grade RWE?) [Link] [LinkedIn]
- Verifying the Source of Data (Not to be Confused with Source Data Verification…Yup! Confusing!) [Link] [LinkedIn]
- The Role of RWE in Health Technology Assessments (HTAs) [Link] [LinkedIn]
- NICE Real World Evidence Framework [Link] [LinkedIn]
- Regulatory Science [Link] [LinkedIn]
- Regulatory Intelligence [Link] [LinkedIn]
- Regulatory Compliance [Link] [LinkedIn]
- The Importance of Regulatory Definitions [Link] [LinkedIn]
- Are the terms ‘clinical study’ and ‘clinical trial’ synonymous in the context of non-interventional studies? [Link] [LinkedIn]
- ‘Interventional’ Clinical Trial vs Non-Interventional Study [Link] [LinkedIn]
- Observational Studies vs Non-Interventional Studies [Link] [LinkedIn]
- NIS vs Market Research [Link] [LinkedIn]
- Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) [Link] [LinkedIn]
- Are Non-Interventional Studies Regulated? [Link] [LinkedIn]
- The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) [Link] [LinkedIn]
- The Tuskegee Syphilis Study – Supplement [Link] [LinkedIn]
- The Common Rule [Link] [LinkedIn]
- HIPAA [Link] [LinkedIn]
- Seeding Studies [Link] [LinkedIn]
- Why Should Non-Interventional Studies NOT be Promotional? [Link] [LinkedIn]
- Principles for Ensuring that Research Results are Reliable, Valid, and Objective [Link] [LinkedIn]
- Disease Prevalence vs Incidence [Link] [LinkedIn]
- Benefits of RWE in the Context of Rare Diseases [Link] [LinkedIn]
- Parkinson’s Disease [Link] [LinkedIn]
- How RWE is Being Used to Support the Treatment of Cancer [Link] [LinkedIn]
- Safety Monitoring [Link] [LinkedIn]
- Categories of PASS [Link] [LinkedIn]
- PASS Approval Requirements [Link] [LinkedIn]
- Protocol Considerations [Link] [LinkedIn]
- Study Designs [Link] [LinkedIn]
- Protocol Design and Scientific Best Practices [Link] [LinkedIn]
- Protocol Design and ISPE GPP [Link] [LinkedIn]
- STaRT-RWE [Link] [LinkedIn]
- HARPER [Link] [LinkedIn]
- Patient Recruitment [Link] [LinkedIn]
- Patient Retention [Link] [LinkedIn]
- Consent to Participate in Research vs Consent to Access and Process Sensitive Healthcare Data (GDPR) [Link] [LinkedIn]
- eConsent [Link] [LinkedIn]
- Monitoring [Link] [LinkedIn]
- Study Conduct [Link] [LinkedIn]
- ISF vs TMF [Link] [LinkedIn]
- TMF Reference Model versus the Real-World Study Document Index (RWS-DI) [Link] [LinkedIn]
- Study Close-Out [Link] [LinkedIn]
- Archiving Generics [Link] [LinkedIn]
- Archiving Specifics [Link] [LinkedIn]
- Publications [Link] [LinkedIn]
- Standard Operating Procedures [Link] [LinkedIn]
- SOPs and Regional Regulations [Link] [LinkedIn]
- Compliance Maps [Link] [LinkedIn]
- Audits [Link] [LinkedIn]
- Inspections [Link] [LinkedIn]
- Audits vs Inspections [Link] [LinkedIn]
- The Importance of Intent [Link] [LinkedIn]
- Ethical Imperatives [Link] [LinkedIn]
- Ethical Imperatives (CIOMS 2023) [Link] [LinkedIn]
- Project Managers [Link] [LinkedIn]
- Evolution of Regulatory Affairs [Link] [LinkedIn]
- RWE – A Career of Many Pathways [Link] [LinkedIn]
- ICH GCP (R3) – Real World Evidence Context [Link] [LinkedIn]
